Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2009 Jul 9

PMID 19584166

Citations 51

Authors

Chirayu Shah

Todd W Miller

Shelby K Wyatt

Eliot T McKinley

Maria Graciela Olivares

Violeta Sanchez

Donald D Nolting

Jason R Buck

Ping Zhao

M Sib Ansari

Ronald M Baldwin

John C Gore

Rachel Schiff

Carlos L Arteaga

H Charles Manning

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate noninvasive imaging methods as predictive biomarkers of response to trastuzumab in mouse models of HER2-overexpressing breast cancer. The correlation between tumor regression and molecular imaging of apoptosis, glucose metabolism, and cellular proliferation was evaluated longitudinally in responding and nonresponding tumor-bearing cohorts.

Experimental Design: Mammary tumors from MMTV/HER2 transgenic female mice were transplanted into syngeneic female mice. BT474 human breast carcinoma cell line xenografts were grown in athymic nude mice. Tumor cell apoptosis (NIR700-Annexin V accumulation), glucose metabolism [2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography ([18F]FDG-PET)], and proliferation [3'-[18F]fluoro-3'-deoxythymidine-PET ([18F]FLT-PET)] were evaluated throughout a biweekly trastuzumab regimen. Imaging metrics were validated by direct measurement of tumor size and immunohistochemical analysis of cleaved caspase-3, phosphorylated AKT, and Ki67.

Results: NIR700-Annexin V accumulated significantly in trastuzumab-treated MMTV/HER2 and BT474 tumors that ultimately regressed but not in nonresponding or vehicle-treated tumors. Uptake of [18F]FDG was not affected by trastuzumab treatment in MMTV/HER2 or BT474 tumors. [18F]FLT-PET imaging predicted trastuzumab response in BT474 tumors but not in MMTV/HER2 tumors, which exhibited modest uptake of [18F]FLT. Close agreement was observed between imaging metrics and immunohistochemical analysis.

Conclusions: Molecular imaging of apoptosis accurately predicts trastuzumab-induced regression of HER2+ tumors and may warrant clinical exploration to predict early response to neoadjuvant trastuzumab. Trastuzumab does not seem to alter glucose metabolism substantially enough to afford [18F]FDG-PET significant predictive value in this setting. Although promising in one preclinical model, further studies are required to determine the overall value of [18F]FLT-PET as a biomarker of response to trastuzumab in HER2+ breast cancer.

Citing Articles

Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models.

Mansur A, Song P, Lu Y, Burns A, Sligh L, Yang E Biomedicines. 2023; 11(8).

PMID: 37626587 PMC: 10452700. DOI: 10.3390/biomedicines11082090.

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.

Bai J, Qiu S, Zhang G Signal Transduct Target Ther. 2023; 8(1):89.

PMID: 36849435 PMC: 9971190. DOI: 10.1038/s41392-023-01366-y.

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.

Song P, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S Cancers (Basel). 2022; 14(4).

PMID: 35205763 PMC: 8869800. DOI: 10.3390/cancers14041015.

Early Changes in [F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts.

Dockx Y, Vangestel C, Van den Wyngaert T, Huizing M, De Bruycker S, Pauwels P Mol Imaging. 2021; 2021:5594514.

PMID: 34113218 PMC: 8169268. DOI: 10.1155/2021/5594514.

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.

Rybinska I, Sandri M, Bianchi F, Orlandi R, De Cecco L, Gasparini P Cells. 2020; 9(2).

PMID: 32069815 PMC: 7072535. DOI: 10.3390/cells9020434.

References

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14(3):737-44. DOI: 10.1200/JCO.1996.14.3.737. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

McDermott G, Welch A, Staff R, Gilbert F, Schweiger L, Semple S . Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2006; 102(1):75-84. DOI: 10.1007/s10549-006-9316-7. View

Plas D, Thompson C . Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005; 24(50):7435-42. DOI: 10.1038/sj.onc.1209097. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Valabrega G, Montemurro F, Aglietta M . Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007; 18(6):977-84. DOI: 10.1093/annonc/mdl475. View

Majumder P, Febbo P, Bikoff R, Berger R, Xue Q, McMahon L . mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10(6):594-601. DOI: 10.1038/nm1052. View

Reyzer M, Caldwell R, Dugger T, Forbes J, Ritter C, Guix M . Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res. 2004; 64(24):9093-100. DOI: 10.1158/0008-5472.CAN-04-2231. View

Rudin M, Weissleder R . Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003; 2(2):123-31. DOI: 10.1038/nrd1007. View

10.

DeNardo S . Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging. J Nucl Med. 2006; 47(1):4-5. View

11.

Manning H, Merchant N, Foutch A, Virostko J, Wyatt S, Shah C . Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res. 2008; 14(22):7413-22. PMC: 2657180. DOI: 10.1158/1078-0432.CCR-08-0239. View

12.

Czernin J, Weber W, Herschman H . Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006; 57:99-118. DOI: 10.1146/annurev.med.57.080904.190431. View

13.

Fueger B, Czernin J, Hildebrandt I, Tran C, Halpern B, Stout D . Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006; 47(6):999-1006. View

14.

Finkle D, Quan Z, Asghari V, Kloss J, Ghaboosi N, Mai E . HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res. 2004; 10(7):2499-511. DOI: 10.1158/1078-0432.ccr-03-0448. View

15.

Yakes F, Chinratanalab W, Ritter C, King W, Seelig S, Arteaga C . Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62(14):4132-41. View

16.

Guix M, de Matos Granja N, Meszoely I, Adkins T, Wieman B, Frierson K . Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008; 26(6):897-906. DOI: 10.1200/JCO.2007.13.5939. View

17.

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

18.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L . Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007; 99(9):694-705. DOI: 10.1093/jnci/djk151. View

19.

Carter P, Presta L, Gorman C, Ridgway J, Henner D, Wong W . Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. PMC: 49066. DOI: 10.1073/pnas.89.10.4285. View

20.

Mohsin S, Weiss H, Gutierrez M, Chamness G, Schiff R, DiGiovanna M . Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005; 23(11):2460-8. DOI: 10.1200/JCO.2005.00.661. View